CIENCIASMEDICASNEWS: FDA investigating risk of severe hypocalcemia in patients on dialysis receiving osteoporosis medicine Prolia (denosumab) | FDA

martes, 22 de noviembre de 2022

FDA investigating risk of severe hypocalcemia in patients on dialysis receiving osteoporosis medicine Prolia (denosumab) | FDA

FDA investigating risk of severe hypocalcemia in patients on dialysis receiving osteoporosis medicine Prolia (denosumab) | FDA

No hay comentarios:

Publicar un comentario

Suscribirse a: Enviar comentarios (Atom)